Synetrim® CQ is a multi-patented (protected by five U.S. patents), multifunctional nutraceutical ingredient that helps reduce weight and body fat through a unprecedented variety of mechanisms of action while contributing to overall metabolic health.

What is Synetrim® CQ?

Dieting results in stress which can lead to:

  • Synetrim® CQ is an all natural, standardized extract of Cissus quadrangularis, a culinary botanical native to India and West Africa with a long history of human consumption. Cissus is a member of the grape family.
  • Synetrim® CQ is the only Cissus quadrangularis extract that is patented for weight loss and metabolic function.

Why Synetrim® CQ is the Superior Choice?

  • Safe and All Natural-Pure Water Extraction
  • GRAS Affirmation Pending
  • Multi-Patented
  • Clinically Proven
  • Excellent Safety Profile
  • Substantiated Structure/Function Claims
  • Multifunctional Ingredient
  • Water Soluble, Vegetarian, Kosher

Mechanism of Action

SensorilTrim® is the perfect complementary ingredient to any new or existing weight loss product because it “takes the stress out of dieting”

  • Synetrim® CQ helps inhibit the absorption of dietary fat and starch and plays a significant role in limiting the impact of calories associated with their consumption.
  • It does this by blocking digestive enzymes that break down fat, starch, and starch-derived sugar. Synetrim® CQ also helps control emotional eating while enhancing lean muscle mass.
  • Synetrim® CQ possesses alpha-amylase and alpha-glucosidase enzyme inhibitory properties. These enzymes digest starch and convert it into glucose for absorption in the body.
  • This inhibition process slows the rate at which starch-derived glucose is absorbed which reduces the number of calories that enter the bloodstream after a carbohydrate rich meal to aid in weight loss.
  • Synetrim® CQ has lipase inhibition properties. Lipase is the enzyme that breaks down dietary fat for absorption in the body.
  • This inhibition process reduces the amount of fat that is absorbed and lessens the caloric impact of ingested fats for improved healthy weight management.

Synetrim® CQ Clinical Research

  • This multidimensional weight management benefits of Synetrim® CQ have been investigated in multiple human trials.
  • In these trials, consumption of the suggested does of Synetrim® CQ by subjects led to significant reductions in weight, body fat, waist size, total cholesterol, LDL,triglycerides, and blood sugar.

Synetrim® CQ Weight Management Claims

  • Promotes healthy weight management*
  • Helps provide clinically proven multi-functional weight management activity*
  • Helps promote clinically proven weight loss activity*
  • Helps inhibit the absorption of dietary fat and starch
  • Clinically proven to promote weight loss activity*
  • Supports weight loss*
  • Clinically proven weight loss ingredient*
  • Helps promote weight loss*
  • Helps support multi-functional weight management activity*
  • Helps promote effective multi-functional weight loss activity*
  • Promotes a multi-functional approach to effective weight loss*
  • Helps promote lean muscle mass*

Weight Management Claims

Synetrim CQ’s clinically proven properties substantiate the following metabolic wellness structure/function claim areas:

  • Metabolic Balance/Wellness
  • Cardiovascular Health
  • Inflammation Response
  • Blood Sugar Balance
  • Supports healthy cardiovascular function*
  • Helps support cholesterol levels which are already within the normal range*
  • Helps support blood sugar levels which are already within the normal range*
  • Supports weight management and metabolic balance/wellness*
  • Helps to regulate and balance healthy metabolic function*

Clinical Trial Features 2007 Study

64 healthy, obese participants (defined as BMI 30 or greater) Two dosage protocols
  • 150 mg BID before meals
  • Placebo
6 week study
2100 kcal/day

Clinical Trial Results 2007 Study

p-value of treatment group versus placebo p < 0.05, body weight

  • Total Cholesterol
  • Triglycerides
  • Serotonin
  • Creatinine
  • 18%
  • 21.7%
  • 53.4%
  • 23.5%
  • Reduction
  • Reduction
  • Increase
  • Increase

p-value of treatment group versus placebo p < 0.05, Total Cholesterol, Serotonin and Creatinine p < 0.001 Triglycerides

Clinical Trial Features 2008 Study

48 healthy, overweight/obese participants (defined as BMI 25 or greater) Two dosage protocols
  • 150 mg BID before meals
  • Placebo
10 week study

Clinical Trial Results 2008 Study

  • Body Weight
  • Body Fat
  • Waist Size
  • Total Cholesterol
  • LDL
  • Fasting Blood Sugar
  • 19.2 lb
  • 14.6%
  • 3.4 inch
  • 26.7%
  • 20.1%
  • 14.8%
  • Reduction
  • Reduction
  • Reduction
  • Reduction
  • Reduction
  • Reduction

p-value of treatment group versus placebo p < 0.05, Total Cholesterol, Fasting Blood Sugar, p < 0.001 LDL

[ClOSE]